Physiological and Clinical Changes After Tricuspid Repair

After the recent announcement by the US Food and Drug Administration (FDA) green-lighting transcatheter aortic valve replacement (TAVR) in patients across the whole spectrum, and given the advancements regarding devices already in the market (such as MitraClip) and a variety of pulmonary valves, there is only one territory left to conquer: the long forgotten tricuspid valve. Its status has resulted in many editorials literally calling it “the forgotten valve” (EuroIntervention 2017; 12: e1799-e1801).

Cambios fisiológicos y clínicos luego de reparar la tricúspide

This study analyzed the impact of chronic right ventricular volume overload and its outcomes after tricuspid regurgitation reduction on biventricular function.

Transcatheter tricuspid “edge-to-edge” repair is a new treatment option for patients with tricuspid regurgitation at high surgical risk.

A total of 29 patients with severe isolated tricuspid regurgitation received treatment using the MitraClip system. Follow-up was conducted using cardiac magnetic resonance at 1 and 6 months.


Read also: Impact of Edge to Edge Transcatheter Tricuspid Valve Repair.


Regurgitant fraction was reduced from 41% to 21% (p < 0.01) without any increase in the right ventricular afterload. The right ventricular end-diastolic volume and the right ventricular stroke volume were reduced significantly, while the effective antegrade flow increased.

This also improved the left ventricular filling with an increase in the end-diastolic volume and the stroke volume: ultimately, an augmentation of cardiac indices (2.2 ± 0.6 L/min/m² vs. 2.7 ± 0.6 L/min/m²; p < 0.01). These results at one month were still true at 6 months.

After the procedure, patient New York Heart Association functional class significantly improved, peripheral edema significantly decreased, and the 6-min walk test distance increased by 20% and 22% after 1 and 6 months, respectively.

Conclusion

Transcatheter treatment of tricuspid regurgitation using the MitraClip system reduces chronic right ventricular volume overload without increasing the right ventricular afterload, it improves left ventricular filling and, ultimately, cardiac indices. These changes translate into significant symptomatic improvement for patients.

The biventricular physiological and clinical improvement is maintained at 6 months after the procedure.

Original title:: Physiological and Clinical Consequences of Right Ventricular Volume Overload Reduction After Transcatheter Treatment for Tricuspid Regurgitation.

Reference: Karl-Philipp Rommel et al. J Am Coll Cardiol Intv 2019. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...